Loading...
St. Jude Medical, Inc.
STJ•NYSE
$80.82
$0.00(0.00%)

The company's financials show resilient growth, with revenue advancing from $1.45B in Q1 2016 to $1.50B in Q3 2016. Gross profit remained healthy with margins at 67% in Q3 2016 compared to 66% in Q1 2016. Operating income hit $286.00M last quarter, sustaining a consistent 19% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $390.00M. Net income dropped to $212.00M, while earnings per share reached $0.75. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan